Are you Dr. Rachman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
7601 Canby Ave
Ste 7
Reseda, CA 91335Phone+1 818-757-1919Fax+1 818-757-3134
Summary
- Dr. Ilya Rachman, MD is a board certified internist in Reseda, California. He is currently licensed to practice medicine in California. He is affiliated with Providence Cedars-Sinai Tarzana Medical Center and Cedars-Sinai Medical Center.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Illinois College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2026- American Board of Internal Medicine Internal Medicine
Clinical Trials
- IMX-110 in Patients With Advanced Solid Tumors Start of enrollment: 2018 Feb 15
Publications & Presentations
PubMed
- 69 citationsNanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.Can Sarisozen, Shekhar Dhokai, Edcar G. Tsikudo, Ed Luther, Ilya M. Rachman
European Journal of Pharmaceutics and Biopharmaceutics. 2016-11-01 - 159 citationsEstrogen alters behavior and forebrain c-fos expression in ovariectomized rats subjected to the forced swim testIlya M. Rachman, James R. Unnerstall, Donald W. Pfaff, Rochelle S. Cohen
Proceedings of the National Academy of Sciences of the United States of America. 1998-11-10 - 43 citationsAnti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicinAbraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman, Sean Senn, Vladimir P. Torchilin
Journal of Drug Targeting. 2013-10-28
Press Mentions
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 26th, 2024- Positive Early Results Seen for CAR T-cell Therapy for Myeloma in TrialMay 1st, 2023
- Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment PotentialMarch 23rd, 2023
- Join now to see all
